BRAF and cutaneous mastocytosis: In particular, it will be of interest to examine Spry1 expression levels in CM with mutant NRAS or wild type for both BRAF and NRAS mutations in order to better define what subpopulation of CM patients most likely benefit from a therapy with Spry1 inhibitors.